Comprehensive medication guide to Evamist including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$25–$60 copay depending on plan tier; Evamist is covered by many commercial insurance plans and some Medicare Part D plans. Commercially insured patients may pay as little as $25 through the Padagis savings program (maximum $70 savings per fill). Prior authorization may be required.
Estimated Cash Pricing
$146–$181 retail per bottle (56 sprays); as low as $75 with GoodRx coupon. The Padagis manufacturer savings program allows cash-paying patients to save up to $70 per prescription.
Medfinder Findability Score
60/100
Summarize with AI
On this page
Evamist is a brand-name prescription hormone therapy spray containing estradiol — a naturally occurring form of estrogen. It is the only FDA-approved estrogen therapy delivered as a transdermal spray, manufactured by Padagis and relaunched in 2022. Each spray delivers a precisely measured dose of 1.53 mg of 17β-estradiol.
Evamist is applied once daily to the inner surface of the forearm, where estradiol is absorbed through the skin directly into the bloodstream — bypassing first-pass liver metabolism. This transdermal route is associated with lower blood clot risk compared to oral estrogen formulations.
Evamist is FDA-approved for the treatment of moderate-to-severe vasomotor symptoms (hot flashes and night sweats) due to menopause. It has no generic equivalent as of 2026.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Menopause occurs when the ovaries reduce estrogen production, causing estrogen levels to fall. This decline disrupts the hypothalamus — the brain's temperature regulation center — making it overly sensitive to small temperature changes and triggering sudden waves of heat (hot flashes), sweating, and flushing.
When Evamist is sprayed on the inner forearm, estradiol absorbs through the skin into the dermal capillaries and enters systemic circulation. It binds to estrogen receptors (ERα and ERβ) in the hypothalamus and other tissues, restoring normal temperature sensitivity and reducing vasomotor symptoms. Estradiol also acts on receptors in the vaginal epithelium, bones, cardiovascular system, and brain.
Estradiol from Evamist is metabolized by the liver via CYP3A4 enzymes into less active estrogens (estrone, estriol) and eventually excreted. Because it bypasses the gut and liver on initial absorption (unlike oral estrogen), transdermal estradiol has less impact on clotting factors — a clinically important advantage for patients with VTE risk factors.
1.53 mg/spray — transdermal spray
Starting dose: 1 spray/day on inner forearm; may increase to 2 or 3 sprays/day based on symptom response
3.06 mg/day — transdermal spray (2 sprays)
2 sprays/day on adjacent non-overlapping areas of inner forearm
4.59 mg/day — transdermal spray (3 sprays)
Maximum dose: 3 sprays/day on adjacent areas of inner forearm
Evamist is not on the FDA's official drug shortage list as of 2026. However, many patients encounter availability challenges because Evamist is not stocked at every pharmacy. The medication was off the market for years before its 2022 relaunch by Padagis, and many pharmacies never resumed carrying it as a standard stock item.
The ongoing shortage of estradiol transdermal patches (Vivelle-Dot, Climara, Lyllana) has created significant spillover demand for Evamist as an alternative transdermal option. Combined with a broader surge in HRT prescriptions following the FDA's 2025 removal of the estradiol black box warning, Evamist's demand has outpaced pharmacy stocking at many locations.
To find Evamist in stock near you, use medfinder — a service that calls pharmacies near you to check which ones can fill your Evamist prescription. Results are texted to you. Independent pharmacies and mail-order services (Amazon Pharmacy, Express Scripts) tend to have more reliable supply than large retail chains.
Because Evamist contains estradiol — a non-controlled substance — it can be prescribed by any licensed healthcare provider in the US without DEA registration requirements. Prescriptions can be sent electronically in all states.
OB/GYNs — most common prescribers of HRT
Primary care physicians (family medicine, internal medicine)
Menopause specialists (certified menopause practitioners listed at menopause.org)
Nurse practitioners (NPs) and physician assistants (PAs)
Endocrinologists — especially for complex hormonal cases
Evamist is widely available via telehealth. Platforms specializing in women's health (Alloy Women's Health, Midi Health) can evaluate menopausal symptoms and prescribe Evamist during a virtual visit, often same-day or next-day, with electronic prescriptions sent to any US pharmacy.
No. Evamist is not a controlled substance. It contains estradiol (estrogen), which has no abuse potential and is not scheduled by the DEA under the Controlled Substances Act.
Because Evamist is not a controlled substance, it can be prescribed by any licensed healthcare provider — including primary care physicians, OB/GYNs, nurse practitioners, physician assistants, and telehealth providers. There are no DEA registration requirements or limitations on the quantity that can be prescribed. Prescriptions can be sent electronically in all US states, and telehealth prescribing is fully permitted.
The most common side effects (occurring in 5% or more of patients in clinical trials) include:
Headache
Breast tenderness and nipple pain
Nausea
Back pain
Nasopharyngitis (cold-like symptoms)
Unusual vaginal bleeding (possible sign of endometrial cancer)
Signs of blood clot: leg pain/swelling, chest pain, shortness of breath
Signs of stroke: sudden headache, vision changes, slurred speech, facial drooping
Signs of heart attack: chest pain, jaw/arm pain, sweating
Breast lumps (report immediately; mammograms recommended annually during HRT)
Signs of dementia (in women 65+): memory loss, confusion (boxed warning)
Important: Children must not come into contact with skin where Evamist was applied — secondary estradiol exposure has caused premature puberty signs in children.
Know what you need? Skip the search.
EstroGel / Divigel
Topical estradiol gels applied daily to the arm or thigh; transdermal delivery similar to Evamist; widely available; closest functional alternatives
Estradiol patches (Vivelle-Dot, Climara, Dotti)
Transdermal estradiol patches applied 1-2x weekly; same active ingredient; generic versions available; currently in shortage in many areas
Oral estradiol (Estrace)
Daily oral tablet; generic available; affordable; effective but higher clot risk than transdermal; widely stocked
Premarin
Oral conjugated equine estrogens; one of the most-studied HRT options; widely available; not bioidentical estradiol
Veozah (fezolinetant)
Non-hormonal FDA-approved treatment for moderate-to-severe hot flashes; blocks neurokinin B receptors; appropriate for those who cannot use estrogen
Prefer Evamist? We can find it.
St. John's Wort
majorCYP3A4 inducer — significantly reduces estradiol blood levels, potentially causing breakthrough hot flashes and changes in vaginal bleeding pattern
Rifampin
majorStrong CYP3A4 inducer — reduces estradiol plasma concentrations substantially
Carbamazepine (Tegretol)
moderateCYP3A4 inducer — may reduce estradiol effectiveness
Phenobarbital
moderateCYP3A4 inducer — reduces estradiol levels
Ketoconazole / Itraconazole
moderateCYP3A4 inhibitors — may increase estradiol levels and risk of side effects
Erythromycin / Clarithromycin
moderateCYP3A4 inhibitors — may increase estradiol plasma concentrations
Ritonavir (HIV protease inhibitors)
moderateCYP3A4 inhibitor — may significantly increase estradiol levels
Grapefruit juice
minorInhibits CYP3A4 and intestinal metabolism — moderate amounts may increase estradiol exposure
Aromatase inhibitors (anastrozole, letrozole, exemestane)
majorDirectly antagonizes estradiol's mechanism — using Evamist with aromatase inhibitors (breast cancer treatment) counteracts both drugs; generally contraindicated
Tamoxifen / Raloxifene
majorSERMs that compete with estradiol at receptor level; combined use not recommended outside of specialist oversight
Tranexamic acid
moderateMay increase clotting risk when combined with estrogen therapy
Levothyroxine (thyroid medications)
moderateEstrogens increase thyroid-binding globulin; may require higher levothyroxine doses to maintain euthyroid status
Evamist is a unique and clinically effective option for managing menopausal vasomotor symptoms. As the only FDA-approved estradiol transdermal spray, it offers precise metered dosing, a favorable transdermal absorption profile (lower clot risk vs. oral estrogen), and daily once-application convenience. The lack of a generic version means patients need to budget appropriately and take advantage of available savings programs.
The main challenge with Evamist in 2026 is availability — not every pharmacy stocks it, and increased demand from the estradiol patch shortage means patients may need to search multiple locations. Starting the refill search early, using mail-order pharmacies, and utilizing tools to check local pharmacy stock are essential strategies.
If you've been prescribed Evamist and are having trouble finding it, medfinder can call pharmacies near you to check stock and text you the results — eliminating the frustrating process of calling pharmacies one by one. Don't let supply challenges disrupt your hormone therapy.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini